First TomoTherapy® System in Latin America Dedicated Solely to Breast Cancer Care Now Treating Patients
"We're honored that FUCAM selected the TomoTherapy System as their 'radiation therapy system of choice' to help them achieve their goal of offering breast cancer treatment to all women, regardless of their income," said
The TomoTherapy System is the only radiation system specifically designed for image-guided intensity-modulated radiation therapy (IG-IMRT). Leveraging a CT scanner-based platform, TomoHelical™ Mode enables continuous delivery from 360 degrees around the patient with highly conformal and homogeneous dose to the tumor. A clinician can also choose to deliver treatment from specific fixed angles via TomoDirect™ Mode. With the TomoTherapy System, highly-sculpted dose distributions are achievable for the full range of breast cancer cases, from routine to complex.
"We (FUCAM) are a reference center for breast cancer patients, receiving about 1,000 new cases per year, so it was critical that we select a versatile and efficient radiation therapy system capable of delivering both hypofractionated and non-hypofractionated treatments to address a variety of patient needs," said
FUCAM is a civil partnership with a mission to provide diagnosis and treatment for breast cancer, particularly in the most vulnerable and marginalized in
About the TomoTherapy® System
The TomoTherapy System is capable of treating all standard radiation therapy indications, in addition to complex cases such as total marrow irradiation. Radiation oncologists have treated many types of cancers with the TomoTherapy System, including breast, prostate, lung, head & neck and pediatric. The system efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity modulated radiation for optimal sparing of healthy tissue and critical structures.
About
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the adoption and acceptance of the company's products, clinical experience, clinical applications, clinical results, patient outcomes and
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/first-tomotherapy-system-in-latin-america-dedicated-solely-to-breast-cancer-care-now-treating-patients-300027392.html
SOURCE
Beth Kaplan, Accuray, +1 (408) 789-4426, bkaplan@accuray.com; Kirsten Fallon, MSLGROUP in Boston, +1 (781) 684-0770, Kirsten.Fallon@MSLGROUP.com